Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
Financials ($)
Sales 2017 21 817 M
EBIT 2017 5 975 M
Net income 2017 2 293 M
Debt 2017 12 395 M
Yield 2017 4,20%
Sales 2018 22 081 M
EBIT 2018 5 911 M
Net income 2018 2 688 M
Debt 2018 13 495 M
Yield 2018 4,23%
P/E ratio 2017 32,76
P/E ratio 2018 27,66
EV / Sales2017 4,37x
EV / Sales2018 4,37x
Capitalization 82 988 M
More Financials
AstraZeneca Plc is a holding company, which engages in the research, development and manufacture of pharmaceutical products.The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases.Its... 
More about the company
Surperformance© ratings of AstraZeneca
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTRAZENECA
12/15 ASTRAZENECA : to launch diabetes drug - Xigduo XR in FY18
12/14 ASTRAZENECA : Researchers' Work from AstraZeneca Focuses on Proglucagon (The acu..
12/14 ASTRAZENECA : Investigators at AstraZeneca Target Pharmacology (Systems Pharmaco..
12/14 ASTRAZENECA : Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic L..
12/14 ASTRAZENECA : Research Results from AstraZeneca Update Understanding of Molecula..
12/13 ASTRAZENECA : Mercia invests £350k in software to boost the quality of digital ..
12/12 ASTRAZENECA : Pharma sector warns of 'dire' consequences without Europe regulati..
12/12 ASTRAZENECA : CALQUENCE shows potential in chronic lymphocytic leukemia trials
12/12 ASTRAZENECA : CALQUENCE demonstrates activity in relapsed or refractory mantle c..
12/11 ASTRAZENECA : GSK's new pharma head on lookout for cancer deals to boost pipelin..
More news
Sector news : Pharmaceuticals - NEC
12:38a NELSON PELTZ : P&G appoints Peltz to board despite losing proxy battle
12:38a PROCTER & GAMBLE : P&G appoints Peltz to board despite losing proxy battle
12/15 JAZZ PHARMACEUTICALS : Pennsylvania man admits to trading on tips about drug com..
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ASTRAZENECA 
A rally could take place
More Strategies
News from SeekingAlpha
12/15 AstraZeneca (AZN) Investor Presentation - Slideshow
12/14 AstraZeneca (AZN) Investor Science Late-Stage Conference Call (Transcript)
12/11 AstraZeneca's acalabrutinib shows treatment effect in CLL studies; shares up ..
12/09 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 9, 2017
12/07 Pieris on go with early-stage study of inhaled therapy for treatment-resistan..
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 68,4 $
Spread / Average Target 5,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA9.99%82 988
JOHNSON & JOHNSON24.03%380 546
NOVARTIS13.16%222 673
PFIZER12.81%217 327
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759